Medicines Co shares rise 12% on US settlement with Teva on Angiomax patents
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has settled a US patent infringement lawsuit with The Medicines Company on its anticoagulant Angiomax (bivalirudin for injection), leading to The Medicine Company's shares gaining $1.72 (11.6%) to $16.60. The Medicines Company gains nearly all of its revenues from the one marketed product. The settlement includes a licence to Teva under which Teva can launch generic Angiomax in the US on 30 June 2019. Teva had been seeking to market before certain patents expire in 2028.